Summary of Key Points Core Viewpoint - The company plans to use part of the raised funds to provide interest-free loans to its wholly-owned subsidiary for the implementation of fundraising projects, which has been reviewed and approved by the sponsor institution [1][9]. Fundraising Overview - The company raised a total of RMB 1,109.25 million through its initial public offering, with a net amount of RMB 994.64 million after deducting issuance costs [1]. - The total planned investment for the fundraising projects is RMB 1,771.79 million, with the company intending to allocate RMB 994.64 million from the raised funds [2]. Use of Funds - The company previously provided an interest-free loan of RMB 50 million to its subsidiary Shenzhen Kexing Pharmaceutical for the "R&D Center Upgrade Project" [2][3]. - The current plan includes an additional interest-free loan of RMB 20 million to the same subsidiary for ongoing R&D projects, bringing the total loan amount to RMB 120 million [4][5]. Project Progress - As of June 30, 2025, the cumulative investment in the R&D Center Upgrade Project is RMB 347.46 million, with RMB 290.63 million already utilized, resulting in a shortfall of RMB 56.83 million [4]. - The remaining balance in the dedicated fundraising account for this project is RMB 73.96 million, which includes net income from financial products and bank interest [4]. Financial Data of the Subsidiary - As of December 31, 2024, the subsidiary reported total assets of RMB 535.61 million, net assets of RMB 278.31 million, operating income of RMB 316.77 million, and net profit of RMB 51.75 million [7]. Approval Process - The use of funds for the interest-free loan has been approved by the company's board and supervisory board, complying with relevant regulations [9].

Group 1 - The company achieved profitability in 2024 with a revenue of approximately 1.407 billion yuan (+11.75%), driven by a significant increase in overseas income, which reached about 225 million yuan (+62.07%) [1] - The company reported a net profit attributable to shareholders of approximately 31 million yuan in 2024, recovering from a loss of about 190 million yuan in 2023 [1] - In Q1 2025, the company generated revenue of approximately 354 million yuan (-1.97%), with a net profit attributable to shareholders of about 26 million yuan (+106.21%) [1] Group 2 - The rapid growth of overseas revenue is highlighted, with a year-on-year increase of 84.33% in Q1 2025, following the successful sales of albumin paclitaxel in the EU [2] - The company has covered all emerging market countries with populations over 100 million and GDPs in the top thirty, indicating a strong market presence [2] - By the end of 2024, the company had introduced 16 products and submitted over 120 registration applications in more than 60 countries, with several products expected to be approved for sale in 2025 [2] Group 3 - The company has established five leading technology platforms for drug development, including recombinant protein drugs and antibody drugs, with two assets in Phase III clinical trials [3] - The company has received clinical approval in the US for its inhaled human interferon α1b solution, indicating progress in its innovative drug pipeline [3] Group 4 - The company is expected to see revenue growth from 1.781 billion yuan in 2025 to 2.495 billion yuan in 2027, with net profits projected to increase from 106 million yuan to 253 million yuan during the same period [4] - The current market valuation corresponds to a PE ratio of 72.24X for 2025, 41.80X for 2026, and 30.14X for 2027, suggesting a favorable investment opportunity [4]